福克斯
医学
结直肠癌
内科学
奥沙利铂
阶段(地层学)
肿瘤科
脆弱类杆菌
胃肠病学
组学
佐剂
癌症
抗生素
生物信息学
生物
微生物学
古生物学
作者
Asimina Koulouridi,Ippokratis Messaritakis,Emmanouil Theodorakis,Maria Chondrozoumaki,Maria Sfakianaki,Nikolaos Gouvas,John Tsiaoussis,Dimitriοs Mavroudis,Maria Tzardi,John Souglakos
出处
期刊:Cancers
[MDPI AG]
日期:2021-07-15
卷期号:13 (14): 3552-3552
被引量:3
标识
DOI:10.3390/cancers13143552
摘要
Oxaliplatin-fluoropyrimidine combination therapy is the gold standard treatment for patients with stage III colorectal cancer (CRC); however, treatment duration is now under re-evaluation. The aim of the study was the evaluation of the non-inferiority of three over six months treatment with FOLFOX or CAPOX, in stage III CRC patients. Peripheral blood samples from 121 patients were collected, at three time points during treatment and evaluated for circulating tumor cells (CTCs) and microbial DNA detection (16S rRNA, Escherichia coli, Bacteroides fragilis, Candida albicans). Of all patients, 41.3% and 58.7% were treated with FOLFOX and CAPOX, respectively. CTCs were significantly decreased and increased after three and six months of treatment, respectively. CAPOX tends to reduce the CTCs after 3 months, whereas there is a statistically significant increase of CTCs in patients under FOLFOX after 6 months. A significant correlation was demonstrated between microbial DNA detection and both CTCs detection at baseline and CTCs increase between baseline and three months of treatment. To conclude, the current study provides additional evidence of non-inferiority of three over 6 months of treatment, mainly in patients under CAPOX.
科研通智能强力驱动
Strongly Powered by AbleSci AI